Tibotec grants developing country licenses before new HIV drug is approved
This article was originally published in Scrip
Executive Summary
The J&J subsidiary, Tibotec, has just raised the bar for other pharmaceutical companies by agreeing to give three generic firms non-exclusive licenses to manufacture and market its latest investigational HIV drug, TMC278, for patients in certain developing countries before the product is launched.